Empirical Financial Services LLC d.b.a. Empirical Wealth Management Buys 5,253 Shares of Johnson & Johnson $JNJ

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Johnson & Johnson (NYSE:JNJ) by 6.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 89,256 shares of the company’s stock after purchasing an additional 5,253 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Johnson & Johnson were worth $21,818,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Bleakley Financial Group LLC increased its stake in Johnson & Johnson by 6.1% in the 1st quarter. Bleakley Financial Group LLC now owns 131,874 shares of the company’s stock worth $32,235,000 after acquiring an additional 7,534 shares during the last quarter. V2 Financial group LLC increased its position in Johnson & Johnson by 5.5% in the first quarter. V2 Financial group LLC now owns 2,532 shares of the company’s stock worth $619,000 after purchasing an additional 132 shares during the last quarter. Birinyi Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at $4,162,000. TFR Capital LLC. lifted its position in Johnson & Johnson by 219.1% during the first quarter. TFR Capital LLC. now owns 10,670 shares of the company’s stock valued at $2,608,000 after purchasing an additional 7,326 shares during the last quarter. Finally, Chicago Partners Investment Group LLC lifted its position in Johnson & Johnson by 13.4% during the first quarter. Chicago Partners Investment Group LLC now owns 27,399 shares of the company’s stock valued at $6,195,000 after purchasing an additional 3,229 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ beat Q2 estimates, with EPS of $2.90 and revenue of $25.31 billion, helped by strong pharmaceutical growth from Darzalex, Tremfya and Spravato. Reuters article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $11.60-$11.75 and revenue of about $100.8 billion-$101.4 billion, signaling management confidence in continued growth. Business Wire article
• Positive Sentiment: Jefferies highlighted Spravato’s strong sales growth as a positive read-through for the broader psychedelic/depression-treatment market, reinforcing the value of J&J’s innovative medicines franchise. Proactive Investors article
• Positive Sentiment: Unusual options activity leaned bullish, with traders buying more JNJ call options than usual, suggesting some expectations for upside after earnings.
• Neutral Sentiment: Johnson & Johnson declared a quarterly dividend of $1.34 per share, underscoring its shareholder-return profile and dividend-king status.
• Neutral Sentiment: Stifel maintained a Hold rating with a $260 price target, reflecting a balanced view after the earnings report. TipRanks article
• Negative Sentiment: Despite the beat-and-raise quarter, the stock slipped because investors appeared underwhelmed relative to elevated expectations and are still weighing MedTech softness and talc-related legal risk. MarketBeat article

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Royal Bank Of Canada lifted their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a report on Wednesday, May 13th. Johnson Rice set a $270.00 target price on shares of Johnson & Johnson in a research report on Friday, June 26th. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $261.70.

Johnson & Johnson Stock Performance

JNJ opened at $247.55 on Thursday. The company has a market cap of $595.90 billion, a P/E ratio of 28.62, a price-to-earnings-growth ratio of 2.42 and a beta of 0.24. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $238.64 and its 200-day moving average price is $234.20. Johnson & Johnson has a 52-week low of $159.80 and a 52-week high of $269.43.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.02 billion. During the same quarter in the previous year, the firm earned $2.77 EPS. Johnson & Johnson’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Insider Activity

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.